NYSE·Healthcare·USD
Henter pris…
Værdiansættelse (TTM)
P/E
25,4
48th %ile · 62pEV/EBITDA
—
P/B
2,9
35th %ile · 64pP/S
3,6
49th %ile · 70pEV/Sales
3,8
49th %ile · 70pDiv yield
—
Regnskabsdata (SEC EDGAR)
Årsregnskab (senest 5 år)
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Omsætning | — | — | — | — | — |
| Bruttoresultat | 13.854,0 mio. | 11.490,0 mio. | 9.896,0 mio. | 8.727,0 mio. | 8.177,0 mio. |
| Nettoresultat | — | — | — | — | — |
| Op. cash flow | 4.534,0 mio. | 3.435,0 mio. | 2.503,0 mio. | 1.526,0 mio. | 1.870,0 mio. |
| Capex | 876,0 mio. | 790,0 mio. | 711,0 mio. | 588,0 mio. | 554,0 mio. |
| Free cash flow | 3.658,0 mio. | 2.645,0 mio. | 1.792,0 mio. | 938,0 mio. | 1.316,0 mio. |
| EPS | 1,96 | 1,26 | 1,08 | 0,45 | 0,69 |
| Aktiver i alt | 43.673,0 mio. | 39.395,0 mio. | 35.136,0 mio. | 32.469,0 mio. | 32.229,0 mio. |
| Egenkapital | 24.233,0 mio. | 21.770,0 mio. | 19.282,0 mio. | 17.573,0 mio. | 16.622,0 mio. |
| Rentebærende gæld | — | — | — | — | — |
| Aktier udestående | — | — | — | — | — |
Kvartalsregnskab (senest 4 kvartaler)
| Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|
| Omsætning | — | — | — | — |
| Bruttoresultat | 10.175,0 mio. | 6.633,0 mio. | 3.210,0 mio. | — |
| Nettoresultat | — | — | — | — |
| Op. cash flow | 3.170,0 mio. | 1.827,0 mio. | 541,0 mio. | — |
| Capex | 525,0 mio. | 344,0 mio. | 187,0 mio. | — |
| Free cash flow | 2.645,0 mio. | 1.483,0 mio. | 354,0 mio. | — |
| EPS | 1,50 | 0,99 | 0,46 | — |
| Aktiver i alt | 42.707,0 mio. | 41.559,0 mio. | 40.140,0 mio. | 39.395,0 mio. |
| Egenkapital | 23.394,0 mio. | 22.418,0 mio. | 22.212,0 mio. | 21.770,0 mio. |
| Rentebærende gæld | — | — | — | — |
| Aktier udestående | — | — | — | — |